Antonini A, Barone P, Calabresi P, Lopiano L, Morgante F, Pontieri FE, Sensi M, Stocchi F (2023) The role of opicapone in the management of Parkinson’s disease: an Italian consensus through a combined nominal group technique and Delphi approach. Eur Rev Med Pharmacol Sci 27:8850–8859. https://doi.org/10.26355/eurrev_202309_33805

Article  CAS  PubMed  Google Scholar 

Bacchin R, Liccari M, Catalan M, Antonutti L, Manganotti P, Malaguti MC, Giometto B (2024) Disease stage and motor fluctuation duration predict drug tolerability: a real-life, prospective Italian multicenter study on the use of opicapone in Parkinson’s disease. Drugs Real World Outcomes 11:361–368. https://doi.org/10.1007/s40801-024-00442-1

Article  PubMed  PubMed Central  Google Scholar 

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X

Article  CAS  PubMed  Google Scholar 

Bovenzi R, Conti M, Degoli GR, Cerroni R, Simonetta C, Liguori C, Salimei C, Pisani A, Pierantozzi M, Stefani A, Mercuri NB, Schirinzi T (2023a) Shaping the course of early-onset Parkinson’s disease: insights from a longitudinal cohort. Neurol Sci 44:3151–3159. https://doi.org/10.1007/s10072-023-06826-5

Article  PubMed  PubMed Central  Google Scholar 

Bovenzi R, Sancesario GM, Conti M, Grillo P, Cerroni R, Bissacco J, Forti P, Giannella E, Pieri M, Minosse S, Ferrazzoli V, Pucci N, Laudazi M, Floris R, Garaci F, Pierantozzi M, Stefani A, Mercuri NB, Picchi E, Di Giuliano F, Schirinzi T (2023b) Sex hormones differentially contribute to Parkinson disease in males: a multimodal biomarker study. Eur J Neurol 30:1983–1990. https://doi.org/10.1111/ene.15801

Article  PubMed  Google Scholar 

Bovenzi R, Conti M, De Franco V, Pierantozzi M, Schirinzi T, Cerroni R, Stefani A, Mercuri NB, Liguori C (2024) Sex differences in Parkinson’s disease-related non motor symptoms: a focus on sleep problems. Acta Neurol Belg 124:1525–1534. https://doi.org/10.1007/s13760-024-02535-8

Article  PubMed  PubMed Central  Google Scholar 

Bovenzi R, Conti M, Simonetta C, Bissacco J, Mascioli D, Michienzi V, Pieri M, Cerroni R, Liguori C, Pierantozzi M, Stefani A, Mercuri NB, Schirinzi T (2025) Contribution of testosterone and estradiol in sexual dimorphism of early-onset Parkinson’s disease. J Neural Transm (Vienna) 132:61–66. https://doi.org/10.1007/s00702-024-02811-0

Article  CAS  PubMed  Google Scholar 

Conti V, Izzo V, Russillo MC, Picillo M, Amboni M, Scaglione CLM, Nicoletti A, Cani I, Cicero CE, De Bellis E, Charlier B, Giudice V, Somma G, Corbi G, Barone P, Filippelli A, Pellecchia MT (2022) Gender differences in levodopa pharmacokinetics in levodopa-naive patients with Parkinson’s disease. Front Med (Lausanne) 9:909936. https://doi.org/10.3389/fmed.2022.909936

Article  PubMed  Google Scholar 

Donzuso G, Cicero CE, Vinciguerra E, Sergi R, Luca A, Mostile G, Terravecchia C, Zappia M, Nicoletti A (2023) Gender differences in non-motor fluctuations in Parkinson’s disease. J Neural Transm 130:1249–1257. https://doi.org/10.1007/s00702-023-02679-6

Article  PubMed  Google Scholar 

Feldman M, Margolesky J (2023) Opicapone for the treatment of Parkinson’s disease: a review. Int J Neurosci 133:532–543. https://doi.org/10.1080/00207454.2021.1929217

Article  CAS  PubMed  Google Scholar 

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P (2019) Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 26:953–960. https://doi.org/10.1111/ene.13914

Article  CAS  PubMed  Google Scholar 

Ferreira JJ, Lee JY, Ma HI, Jeon B, Poewe W, Antonini A, Stocchi F, Rodrigues DM, Fonseca MM, Castilla-Fernández G, Holenz J, Rocha JF, Rascol O, ADOPTION study investigators (2024) Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies. J Neurol 271:6729–6738. https://doi.org/10.1007/s00415-024-12614-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

GBD Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23(4):344–381. https://doi.org/10.1016/S1474-4422(24)00038-3

Article  Google Scholar 

Hauser RA, Videnovic A, Soares-da-Silva P, Liang GS, Olson K, Jen E, Rocha JF, Klepitskaya O (2024) OFF-times before, during, and after nighttime sleep periods in Parkinson’s disease patients with motor fluctuations and the effects of opicapone: a post hoc analysis of diary data from BIPARK-1 and -2. Parkinsonism Relat Disord 123:106971. https://doi.org/10.1016/j.parkreldis.2024.106971

Article  PubMed  Google Scholar 

Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Rev Neurother 21(9):1019–1033. https://doi.org/10.1080/14737175.2021.1968298

Article  CAS  PubMed  Google Scholar 

Jost WH (2022) Evaluating opicapone as add-on treatment to levodopa/DDCI in patients with Parkinson’s disease. Neuropsychiatr Dis Treat 18:1603–1618. https://doi.org/10.2147/NDT.S279362

Article  PubMed  PubMed Central  Google Scholar 

Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41:202–205. https://doi.org/10.1212/wnl.41.2_part_1.202

Article  CAS  PubMed  Google Scholar 

Kostíc VS, Marinković J, Svetel M, Stefanova E, Przedborski S (2002) The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 9:9–14. https://doi.org/10.1046/j.1468-1331.2002.00346.x

Article  PubMed  Google Scholar 

LeWitt PA (2015) Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord 30:64–72. https://doi.org/10.1002/mds.26082

Article  CAS  PubMed  Google Scholar 

Lock EA, Zhang J, Checkoway H (2013) Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence. Toxicol Appl Pharmacol 266:345–355. https://doi.org/10.1016/j.taap.2012.11.016

Article  CAS  PubMed  Google Scholar 

López-Ariztegui N, Mata-Alvarez Santullano M, Tegel I, Almeida F, Sarasa P, Rojo R, Rico-Villademoros F, Abril-Jaramillo J, Bermejo P, Borrue C, Caballol N, Campins-Romeu M, Clavero P, García-Caldentey J, Gómez-Mayordomo V, Labandeira C, Martí-Andrés G, Martínez-Castrillo JC, Martinez-Poles J, Muñoz T, Salom JM, Valderrama-Martin C, Vinagre-Aragón A (2021) Opicapone for the treatment of Parkinson’s disease: real-life data in Spain. Rev Neurol 73:S01-S14. https://doi.org/10.33588/rn.73s02.2021461. (in Spanish)

Article  PubMed  Google Scholar 

Meira-Carvalho F, Da Silva JD, Rodrigues M (2021) Opicapone in Parkinson’s disease: real-world data from a Portuguese center. Eur Neurol 84:129–131. https://doi.org/10.1159/000514544

Article  CAS  PubMed  Google Scholar 

Muñoz Ruiz T, Pons Pons G, Garcia Trujillo L, Martínez Tomás C, Serrano Casto P (2020) Which factors predict the succes of opicapone? Defining the optimal patient profile [EAN abstract EPO3131]. Eur Neurol 27:1095. https://doi.org/10.1111/ene.14308

Article  Google Scholar 

Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for Parkinson’s disease: current status and future opportunities. Mov Disord 35:1731–1744. https://doi.org/10.1002/mds.28215

Article  PubMed  Google Scholar 

Patel R, Kompoliti K (2023) Sex and gender differences in Parkinson’s disease. Neurol Clin 41:371–379. https://doi.org/10.1016/j.ncl.2022.12.001

Article  PubMed  Google Scholar 

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424

Article  PubMed  Google Scholar 

Rastgardani T, Armstrong MJ, Gagliardi AR, Grabovsky A, Marras C (2020) Experience and impact of OFF periods in Parkinson’s disease: a survey of physicians, patients, and carepartners. J Parkinsons Dis 10:315–324. https://doi.org/10.3233/JPD-191785

Article  PubMed  Google Scholar 

Reichmann H, Lees A, Rocha JF, Magalhães D, Soares-da-Silva P, OPTIPARK investigators (2020) Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener 9:9. https://doi.org/10.1186/s40035-020-00187-1

Article